A3P Biomedical has appointed Anders Martin-Löf as Chief Financial Officer (CFO). Anders Martin-Löf brings more than 20 years’ experience from the life science industry, including CFO positions at Oncopeptides, Wilson Therapeutics and RaySearch Laboratories. He will take up his new position at A3P Biomedical in August and report to CEO David Rosén.
“I am very pleased that we have been able to recruit Anders Martin-Löf as our new CFO. With broad experience from the industry and several challenging CFO positions, Anders will be a great addition to the management team. Following our recent successfully completed private placement, we are now able to accelerate the commercial expansion of Stockholm3 and offer significantly improved prostate cancer diagnostics to more healthcare providers and men. I look forward to working closely with Anders and would also like to thank our board member Cecilia Edström for stepping in as acting CFO during the recruitment process,” says David Rosén CEO of A3P Biomedical.
“Stockholm3 can make a big difference in the fight against cancer and I believe that there is great potential both for patients and health-care providers in using it as standard of care for early detection of prostate cancer, the second most common cancer in men worldwide. I am really excited about joining A3P Biomedical and look forward to contributing to the global clinical roll-out, and increased patient and shareholder value,” says Anders Martin-Löf.
Anders Martin-Löf is 50 years old and holds an MSc in Engineering Physics, from the Royal Institute of Technology (KTH), and BA major in business administration, from the Stockholm and Uppsala Universities. Most recently, he has been CFO of Oncopeptides AB and prior to that, he served as CFO of Wilson Therapeutics AB and RaySearch Laboratories AB. Anders Martin-Löf also has experience from various commercial positions in the life science industry and as a management consultant at the Boston Consulting Group.
Anders Martin-Löf will take up his new position in mid-August and succeeds Cecilia Edström who has been acting CFO since February 2022.